BNT-141

N/A

Report date: 2024/08/23 13:30:55

Base Information

Drug NameBNT-141
Drug Alias NameBNT-141
ClassificationBiologics
Mechanisms of ActionCytotoxic T lymphocytes stimulantsAnti-CLDN18
TargetsClaudin-18 splice variant 2
Therapy Area/IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsSolid tumours +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesGermany
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBiontech Se
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiontech Se
Active IndicationsN/A
Inactive IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsSolid tumours +[8] 

Other Information

ATC CodeN/A
Related LinksN/A